Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Rieder MJ, et al. Among authors: eby cs. N Engl J Med. 2005 Jun 2;352(22):2285-93. doi: 10.1056/NEJMoa044503. N Engl J Med. 2005. PMID: 15930419 Free article.
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF. Voora D, et al. Among authors: eby cs. Clin Pharmacol Ther. 2010 Apr;87(4):445-51. doi: 10.1038/clpt.2009.291. Epub 2010 Mar 3. Clin Pharmacol Ther. 2010. PMID: 20200517 Free PMC article.
Use of pharmacogenetics to guide warfarin therapy.
Voora D, McLeod HL, Eby C, Gage BF. Voora D, et al. Drugs Today (Barc). 2004 Mar;40(3):247-57. doi: 10.1358/dot.2004.40.3.820088. Drugs Today (Barc). 2004. PMID: 15148533
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Gage BF, et al. Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27. Clin Pharmacol Ther. 2008. PMID: 18305455 Free PMC article.
Estimation of the warfarin dose with clinical and pharmacogenetic data.
International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. International Warfarin Pharmacogenetics Consortium, et al. N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. N Engl J Med. 2009. PMID: 19228618 Free PMC article.
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Voora D, et al. Thromb Haemost. 2005 Apr;93(4):700-5. doi: 10.1160/TH04-08-0542. Thromb Haemost. 2005. PMID: 15841315
The pharmacogenetics of coumarin therapy.
Voora D, McLeod HL, Eby C, Gage BF. Voora D, et al. Pharmacogenomics. 2005 Jul;6(5):503-13. doi: 10.2217/14622416.6.5.503. Pharmacogenomics. 2005. PMID: 16014000 Review.
Genetic-based dosing in orthopedic patients beginning warfarin therapy.
Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF. Millican EA, et al. Blood. 2007 Sep 1;110(5):1511-5. doi: 10.1182/blood-2007-01-069609. Epub 2007 Mar 26. Blood. 2007. PMID: 17387222 Free PMC article. Clinical Trial.
109 results